An arduous consensus is taking root- the push for over the counter availability of HCQ in New Zealand
On the 19th of September, New Zealand’s largest local media, the New Zealand Herald published an Australian article regarding a double-blind experiment of hydroxychloroquine sulfate titled “Covid 19 coronavirus: Hydroxychloroquine: The drug that could be our saviour”. For many local supporters of the whistle-blower movement, this was a pleasant surprise. Although the article was simply a reprint, the act of publishing the report itself is telling. We must acknowledge the promotional efforts made by all our supporters.
The reporting by local media regarding the truth of Covid-19 including HCQ has been extremely limited. What little is reported has been overwhelmingly negative. The New Zealand government allocated funds in April of this year to conduct research on the effectiveness of hydroxychloroquine and several other drugs in the treatment of the CCP virus. However, this effort was terminated within weeks supposedly due to a lack of positive case numbers in New Zealand. It is clear that the narrative effectively mirrors that of the World Health Organization (WHO). Since then, HCQ has rarely been mentioned in New Zealand’s mainstream media. Even conducting a generic search for ‘hydroxychloroquine’ as a keyword on government agency websites including the Ministry of Health and Parliament yield zero results. ······ [Read more] “An arduous consensus is taking root- the push for over the counter availability of HCQ in New Zealand”